Cormorant Asset Management, LP Ventyx Biosciences, Inc. Transaction History

Cormorant Asset Management, LP

  • $1.43 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$1.9 - $10.13 $5.15 Million - $27.5 Million
2,710,000 New
2,710,000 $14.9 Million
Q4 2022

Feb 14, 2023
BUY
$24.16 - $36.38 $7.25 Million - $10.9 Million
299,997 Added 38.43%
1,080,643 $35.4 Million
Q3 2022

Nov 14, 2022
BUY
$12.64 - $38.7 $37 - $116
3 Added 0.0%
780,646 $27.3 Million
Q2 2022

Aug 15, 2022
SELL
$11.95 - $18.75 $55,687 - $87,375
-4,660 Reduced 0.59%
780,643 $9.55 Million
Q4 2021

Feb 14, 2022
BUY
$14.2 - $23.07 $11.2 Million - $18.1 Million
785,303 New
785,303 $15.1 Million

Others Institutions Holding VTYX

# of Institutions
125
Shares Held
52.9M
Call Options Held
35.3K
Put Options Held
83K
View Full List

About Ventyx Biosciences, Inc.

VTYX Quotes by TradingView
  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $132M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email